Glutathione ( DrugBank: Glutathione )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	5
299	嚢胞性線維症	7

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05266417 (ClinicalTrials.gov)	February 7, 2022	23/2/2022	Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, ...	Parkinson Disease	Drug: INS-GSH;Drug: Matched Placebos	Gateway Institute for Brain Research	NULL	Recruiting	30 Years	85 Years	All	56	Phase 2	United States
2	NCT02424708 (ClinicalTrials.gov)	April 2015	15/4/2015	Phase IIb Study of Intranasal Glutathione in Parkinson's Disease	Phase IIb Study of Intranasal Glutathione in Parkinson's Disease	Parkinson's Disease	Drug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: Placebo	Bastyr University	Michael J. Fox Foundation for Parkinson's Research	Completed	21 Years	N/A	Both	45	Phase 2	United States
3	NCT02324426 (ClinicalTrials.gov)	December 2014	4/12/2014	CNS Uptake of Intranasal Glutathione	Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease	Parkinson's Disease	Drug: Reduced Glutathione	University of Washington	Michael J. Fox Foundation for Parkinson's Research	Completed	18 Years	N/A	Both	15	Phase 1	United States
4	NCT01398748 (ClinicalTrials.gov)	July 2012	19/7/2011	Intranasal Glutathione in Parkinson's Disease	A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease	Parkinson's Disease (PD)	Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery	Bastyr University	National Center for Complementary and Integrative Health (NCCIH)	Completed	21 Years	100 Years	All	34	Phase 1	United States
5	NCT01177319 (ClinicalTrials.gov)	September 2003	5/8/2010	Glutathione (GSH) In The Treatment of Parkinson's Disease	Glutathione (GSH) In The Treatment of Parkinson's Disease	Parkinson's Disease	Drug: Glutathione	University of South Florida	Wellness Health & Pharmaceuticals, Inc.	Completed	18 Years	N/A	Both	20	Phase 2	United States

First Previous1Next Last

先頭へ

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03020719 (ClinicalTrials.gov)	June 14, 2017	11/1/2017	The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis	A Multi Center Placebo Controlled Double Blind Randomized Study Evaluating the Role of Oral Glutathi ...	Cystic Fibrosis	Drug: Oral Glutathione;Drug: Placebo	University of Minnesota	Cystic Fibrosis Foundation	Completed	2 Years	11 Years	All	60	Phase 2	United States
2	EUCTR2013-005481-19-DK (EUCTR)	27/05/2014	27/05/2014	High Dose Antioxidant Treatment for Patients with Cystic Fibrosis	High Dose Antioxidant Treatment for Patients with Cystic Fibrosis	Cystic Fibrosis MedDRA version: 17.0;Level: LLT;Classification code 10068288;Term: Cystic fibrosis p ...	Trade Name: Mucolysin INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: ACETYLCYSTEINE Trade ...	Aarhus University Hospital	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Denmark
3	NCT02029521 (ClinicalTrials.gov)	March 2011	30/12/2013	Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients	Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis for Growth Failure	Cystic Fibrosis	Dietary Supplement: Oral reduced l-glutathione;Dietary Supplement: Placebo	Clark Bishop	NULL	Completed	18 Months	10 Years	All	47	N/A	Italy
4	NCT01450267 (ClinicalTrials.gov)	June 2010	30/9/2011	Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis	Randomized, Single Blind, Controlled Trial of Inhaled GlutathioneVersus Placebo in Patients With Cys ...	Cystic Fibrosis	Drug: Inhaled Reduced Glutathione;Drug: Physiological solution	Serafino A. Marsico	Federico II University	Recruiting	6 Years	45 Years	Both	150	Phase 3	Italy
5	EUCTR2008-005080-33-IT (EUCTR)	05/02/2009	19/01/2009	RANDOMIZED, SINGLE BLIND, CONTROLLED TRIAL OF INHALED GLUTATHIONEVERSUS PLACEBO IN PATIENTS WITH CYS ...	RANDOMIZED, SINGLE BLIND, CONTROLLED TRIAL OF INHALED GLUTATHIONEVERSUS PLACEBO IN PATIENTS WITH CYS ...	Cystic fibrosis. MedDRA version: 9.1;Level: LLT;Classification code 10011763;Term: Cystic fibrosis l ...	Trade Name: TAD 600 INN or Proposed INN: Glutathione	AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
6	NCT00506688 (ClinicalTrials.gov)	July 2007	24/7/2007	Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients	Randomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24- ...	Cystic Fibrosis	Drug: reduced glutathione sodium salt;Drug: 0.9% normal saline (control)	Mukoviszidose Institut gGmbH	Cystic Fibrosis Foundation Therapeutics	Completed	8 Years	N/A	Both	153	Phase 2	Germany
7	EUCTR2005-003870-88-DE (EUCTR)	20/10/2006	28/08/2006	Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-we ...	Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-we ...	Cystic fibrosis (CF) is the most common autosomal recessive lethal hereditary disorder in Caucasians ...	Product Name: GSH (Glutathione) Product Code: TAD 600 INN or Proposed INN: Glutathione Other descriptiv ...	Mukoviszidose Institut gGmbH i. G.	NULL	Not Recruiting			Female: yes Male: yes	160		Germany

First Previous1Next Last

先頭へ